Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 18/20 | 0.42 |
| ▸ | AKT1 | P31749 | 18/20 | 0.42 |
| ▸ | AKT2 | P31751 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17401018 | 0.88 | RPS6KB1 (0.44) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL17401024 | 0.87 | TAAR1 (0.44) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL17401012 | 0.83 | CHRNA7 (0.46) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL17401014 | 0.82 | RPS6KB1 (0.42) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| Trifluoroacetic Acid SCHEMBL17396058 | 0.78 | HTR1D (0.40) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| Trifluoroacetic Acid SCHEMBL17396060 | 0.78 | HTR1D (0.40) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL17401025 | 0.73 | TAAR1 (0.39) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL17401084 | 0.73 | TAAR1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL11904101 | 0.73 | MEN1 (0.49) | RPS6KB1AKT1AKT2KCNH2AKT3 | |
| SCHEMBL17401023 | 0.72 | TAAR1 (0.44) | RPS6KB1AKT1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| WO-2016001820-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, IMPA1 | RPS6KB1 2544/4885AKT1 3412/4885AKT2 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.